Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Tuesday.

Other analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 price target on shares of Aclaris Therapeutics in a research report on Tuesday, September 26th. JMP Securities reissued an “outperform” rating and issued a $39.00 price target on shares of Aclaris Therapeutics in a research report on Friday, September 8th. Finally, ValuEngine downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. Aclaris Therapeutics has a consensus rating of “Hold” and a consensus price target of $39.20.

Aclaris Therapeutics (NASDAQ:ACRS) traded down $0.49 during midday trading on Tuesday, reaching $24.23. 2,574,065 shares of the company traded hands, compared to its average volume of 443,418. Aclaris Therapeutics has a twelve month low of $21.32 and a twelve month high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.23. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $2.00 million. equities analysts forecast that Aclaris Therapeutics will post -2.59 earnings per share for the current year.

Large investors have recently modified their holdings of the business. Citigroup Inc. lifted its stake in Aclaris Therapeutics by 171.8% during the 2nd quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 2,726 shares in the last quarter. Legal & General Group Plc lifted its stake in Aclaris Therapeutics by 98.3% during the 2nd quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock valued at $142,000 after acquiring an additional 2,605 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in Aclaris Therapeutics during the 3rd quarter valued at $142,000. Bank of Montreal Can raised its stake in shares of Aclaris Therapeutics by 1,793.1% during the 2nd quarter. Bank of Montreal Can now owns 7,137 shares of the biotechnology company’s stock worth $194,000 after purchasing an additional 6,760 shares during the period. Finally, Voya Investment Management LLC bought a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth $247,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Aclaris Therapeutics (ACRS) Stock Rating Upgraded by BidaskClub” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/17/aclaris-therapeutics-acrs-stock-rating-upgraded-by-bidaskclub.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.